FLX Bio, Inc. announced the appointment of senior pharmaceutical research and development executive Michael F. Giordano to its Board of Directors. Dr. Giordano spent 17 years at Bristol-Myers Squibb (BMS), serving in various development and medical affairs leadership positions across multiple therapeutic areas. Most recently, he served as Senior Vice President and Head of Development, Oncology and Immuno-Oncology where he was responsible for the development strategy of the enterprise for this therapeutic area, as well as direction for eight teams working on innovative medicines to improve the standard of care for patients, including Opdivo, Yervoy, Empliciti, and Sprycel. Prior to this role, Dr. Giordano held positions of increasing responsibility within the research and development organization, leading the development of more than a dozen molecules in the United States, the European Union and Asia. Before joining BMS, he served as Assistant Professor of Medicine and Founding Director of the Cornell Clinical Trials Unit, a National Institutes of Healthand Industry supported AIDS clinical trials center at New York Hospital-Cornell University Medical Center.